BRPI1007990A2 - Compostos específicos de diaril-hidantoína e diariltioidantoína. - Google Patents
Compostos específicos de diaril-hidantoína e diariltioidantoína.Info
- Publication number
- BRPI1007990A2 BRPI1007990A2 BRPI1007990-4A BRPI1007990A BRPI1007990A2 BR PI1007990 A2 BRPI1007990 A2 BR PI1007990A2 BR PI1007990 A BRPI1007990 A BR PI1007990A BR PI1007990 A2 BRPI1007990 A2 BR PI1007990A2
- Authority
- BR
- Brazil
- Prior art keywords
- diarylthioidantoin
- compounds
- specific diaryl
- hydantoin
- diaryl hydantoin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- -1 diaryl hydantoin Chemical compound 0.000 title 1
- 229940091173 hydantoin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15511909P | 2009-02-24 | 2009-02-24 | |
| US15639809P | 2009-02-27 | 2009-02-27 | |
| PCT/US2010/025283 WO2010099238A1 (en) | 2009-02-24 | 2010-02-24 | Specific diarylhydantoin and diarylthiohydantoin compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1007990A2 true BRPI1007990A2 (pt) | 2015-09-01 |
Family
ID=42665887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007990-4A BRPI1007990A2 (pt) | 2009-02-24 | 2010-02-24 | Compostos específicos de diaril-hidantoína e diariltioidantoína. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8524755B2 (pt) |
| EP (1) | EP2400847B1 (pt) |
| JP (2) | JP2012518661A (pt) |
| KR (1) | KR20110130439A (pt) |
| CN (1) | CN102421291A (pt) |
| AU (1) | AU2010218052A1 (pt) |
| BR (1) | BRPI1007990A2 (pt) |
| CA (1) | CA2753425A1 (pt) |
| ES (1) | ES2535466T3 (pt) |
| IL (1) | IL214800A0 (pt) |
| MX (1) | MX2011008858A (pt) |
| NZ (1) | NZ594741A (pt) |
| RU (1) | RU2548918C2 (pt) |
| SG (2) | SG10201402628VA (pt) |
| WO (1) | WO2010099238A1 (pt) |
| ZA (2) | ZA201106200B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| NZ596260A (en) * | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| TWI469971B (zh) | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
| EP2416657A4 (en) * | 2009-04-09 | 2012-09-05 | Medivation Prostate Therapeutics Inc | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF |
| AU2014271290C1 (en) * | 2010-02-16 | 2016-10-27 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| AU2016208310B2 (en) * | 2010-02-16 | 2017-10-05 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| RU2554081C2 (ru) * | 2010-02-24 | 2015-06-27 | Медивэйшн Простейт Терапьютикс, Инк. | Способ синтеза соединений диарилтиогидантоина и диарилгидантоина |
| WO2012123820A1 (en) * | 2011-03-14 | 2012-09-20 | The University Of British Columbia | Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer |
| US9517229B2 (en) | 2011-07-29 | 2016-12-13 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
| WO2013067151A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment methods using diarylthiohydantoin derivatives |
| WO2013067131A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Technologies, Inc. | Treatment methods |
| EP2664325A1 (en) * | 2012-05-16 | 2013-11-20 | PregLem S.A. | Methods for preventing or treating androgen mediated diseases |
| WO2014052237A1 (en) | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| EP2945628B1 (en) | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| WO2014167428A2 (en) * | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| CN104803919A (zh) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | 用于制备恩杂鲁胺中间体的方法 |
| CN104844520B (zh) * | 2014-02-13 | 2017-09-05 | 成都伊诺达博医药科技有限公司 | 一种合成恩杂鲁胺的方法 |
| CN104844521B (zh) * | 2014-02-13 | 2017-08-15 | 成都伊诺达博医药科技有限公司 | 抗前列腺癌药物恩杂鲁胺的合成方法 |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| US10131636B2 (en) * | 2014-10-01 | 2018-11-20 | Laurus Labs Limited | Process for the preparation of Enzalutamide |
| BR112017012142A2 (pt) | 2014-12-12 | 2018-01-02 | Medivation Prostate Therapeutics Inc | método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama |
| TWI613194B (zh) | 2015-06-10 | 2018-02-01 | 台灣神隆股份有限公司 | 用於製備恩雜魯胺的新穎方法 |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| WO2018007624A1 (en) * | 2016-07-08 | 2018-01-11 | Actavis Group Ptc Ehf | Enzalutamide derivatives for the treatment of prostate and breast cancer |
| CN107954936B (zh) * | 2016-10-17 | 2021-03-19 | 海创药业股份有限公司 | 一种制备氘代咪唑二酮类化合物的方法 |
| CN107501237B (zh) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | 一种Apalutamide的合成方法 |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| US20210386826A1 (en) | 2018-11-05 | 2021-12-16 | Pfizer Inc. | Combination for Treating Cancer |
| CN116322693A (zh) | 2020-08-13 | 2023-06-23 | 辉瑞公司 | 组合疗法 |
| PE20240248A1 (es) | 2020-12-11 | 2024-02-19 | Ildong Pharmaceutical Co Ltd | Nuevos compuestos como inhibidor dual del receptor de androgenos y de la fosfodiesterasa |
| EP4313034A1 (en) | 2021-03-24 | 2024-02-07 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
| EP4399517A4 (en) * | 2021-09-08 | 2025-10-15 | Achieve Life Sciences Inc | ANALYTICAL METHODS FOR EVALUATING THE PURITY OF CYTISINE |
| CN117205216B (zh) * | 2022-05-06 | 2026-05-29 | 南京思聚生物医药有限公司 | 一种局部作用的雄激素受体拮抗剂与米诺地尔的组合物及其应用 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5136332B1 (pt) | 1970-12-09 | 1976-10-07 | ||
| FR2715402B1 (fr) * | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
| US7173044B2 (en) | 2004-02-19 | 2007-02-06 | Solvay Pharmaceuticals B.V. | Imidazoline derivatives having CB1-antagonistic activity |
| US20060030871A1 (en) | 2004-08-05 | 2006-02-09 | Matthew Hain | Vascular tunneler |
| CN101006546A (zh) * | 2004-08-26 | 2007-07-25 | 皇家飞利浦电子股份有限公司 | 具有反射涂层的灯 |
| KR20070106969A (ko) * | 2004-09-09 | 2007-11-06 | 추가이 세이야쿠 가부시키가이샤 | 신규 이미다졸리딘 유도체 및 그 용도 |
| WO2006121411A1 (en) * | 2005-05-13 | 2006-11-16 | Protectron Nanocomposites Pte Ltd | Improved colloidal gel for protective fabric, improved protective fabric and method of producing both |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| NZ564223A (en) * | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| NZ596260A (en) | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| TWI469971B (zh) | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
-
2010
- 2010-02-24 JP JP2011551318A patent/JP2012518661A/ja not_active Ceased
- 2010-02-24 SG SG10201402628VA patent/SG10201402628VA/en unknown
- 2010-02-24 CA CA2753425A patent/CA2753425A1/en not_active Abandoned
- 2010-02-24 NZ NZ594741A patent/NZ594741A/en not_active IP Right Cessation
- 2010-02-24 KR KR1020117022048A patent/KR20110130439A/ko not_active Ceased
- 2010-02-24 BR BRPI1007990-4A patent/BRPI1007990A2/pt not_active IP Right Cessation
- 2010-02-24 US US13/202,970 patent/US8524755B2/en active Active
- 2010-02-24 RU RU2011139107/04A patent/RU2548918C2/ru not_active IP Right Cessation
- 2010-02-24 EP EP10746795.3A patent/EP2400847B1/en not_active Revoked
- 2010-02-24 CN CN2010800179543A patent/CN102421291A/zh active Pending
- 2010-02-24 MX MX2011008858A patent/MX2011008858A/es active IP Right Grant
- 2010-02-24 AU AU2010218052A patent/AU2010218052A1/en not_active Abandoned
- 2010-02-24 ES ES10746795.3T patent/ES2535466T3/es active Active
- 2010-02-24 WO PCT/US2010/025283 patent/WO2010099238A1/en not_active Ceased
- 2010-02-24 SG SG2011061066A patent/SG173837A1/en unknown
-
2011
- 2011-08-23 IL IL214800A patent/IL214800A0/en unknown
- 2011-08-23 ZA ZA2011/06200A patent/ZA201106200B/en unknown
-
2013
- 2013-05-14 ZA ZA2013/03499A patent/ZA201303499B/en unknown
- 2013-06-24 US US13/925,507 patent/US9023879B2/en active Active
-
2014
- 2014-11-07 JP JP2014227148A patent/JP2015028085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201106200B (en) | 2013-07-31 |
| US9023879B2 (en) | 2015-05-05 |
| EP2400847A1 (en) | 2012-01-04 |
| CN102421291A (zh) | 2012-04-18 |
| AU2010218052A1 (en) | 2011-09-08 |
| MX2011008858A (es) | 2012-01-27 |
| RU2011139107A (ru) | 2013-04-10 |
| US8524755B2 (en) | 2013-09-03 |
| ES2535466T3 (es) | 2015-05-11 |
| EP2400847A4 (en) | 2012-08-08 |
| US20130331421A1 (en) | 2013-12-12 |
| IL214800A0 (en) | 2011-11-30 |
| WO2010099238A1 (en) | 2010-09-02 |
| JP2012518661A (ja) | 2012-08-16 |
| JP2015028085A (ja) | 2015-02-12 |
| RU2548918C2 (ru) | 2015-04-20 |
| NZ594741A (en) | 2014-03-28 |
| KR20110130439A (ko) | 2011-12-05 |
| US20120035231A1 (en) | 2012-02-09 |
| ZA201303499B (en) | 2015-03-25 |
| SG173837A1 (en) | 2011-09-29 |
| CA2753425A1 (en) | 2010-09-02 |
| EP2400847B1 (en) | 2014-12-17 |
| SG10201402628VA (en) | 2014-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2021006I1 (no) | Quofenix, delafloksacin | |
| BRPI0815717A2 (pt) | Compostos de imidazopirazina. | |
| BRPI1007310A2 (pt) | Compostos inseticidas. | |
| BRPI0807473A2 (pt) | Recipiente, javre e conjunto de recipiente e javre | |
| BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
| BRPI0821868A2 (pt) | Grânulo | |
| FR2943512B1 (fr) | Applicateur metallique. | |
| EP2307845A4 (en) | LOCK HOLSTER | |
| BRPI1009415A2 (pt) | escova de dentes. | |
| BRPI0918430A2 (pt) | 4-fenil-1h-pirazóis inseticidas. | |
| BRPI1016117A2 (pt) | derivados de isoxazol-isoxazol e isoxasol-isotiazol. | |
| BRPI0907108A2 (pt) | escova de dentes. | |
| BRPI1011460A2 (pt) | Composição desinfetante. | |
| SE0801651L (sv) | Granuleringskvarn | |
| EP2259958A4 (en) | LINKAGE | |
| IT1396487B1 (it) | Convogliatore. | |
| BRPI0912716A2 (pt) | composto. | |
| BRPI0922728A2 (pt) | combinação de herbicida-antídoto | |
| IT1391534B1 (it) | Barriera. | |
| BRPI0920116A2 (pt) | membro de vedação | |
| BRPI1014244A2 (pt) | composto de polipropileno-talco estabilizado. | |
| IT1396642B1 (it) | Statore. | |
| DE112009001669A5 (de) | Sektionaltor | |
| EP2256754A4 (en) | REACTOR | |
| FR2935945B1 (fr) | Installation de telepherique. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |